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Abstract: One of the major toxins secreted by H. pylori is the Vacuolating cytotoxin A (VacA) named
after its ability to induce the formation of “vacuole”-like membrane vesicles in the cytoplasm of
gastric cells. VacA has been associated with the disruption of mitochondrial functions, stimulation
of apoptosis, blockade of T cell proliferation and promotion of regulatory T cells, thereby making it
a promising vaccine target. Immunity to bacterial virulence factors is well known to protect humans
against bacterial infections; hence, detoxified VacA has been evaluated as a vaccine antigen. Our short
review summarizes the pre-clinical and clinical data that have been published on the use of VacA in
the development of the H. pylori vaccine.
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1. Introduction
Helicobacter pylori infection is one of the most common infections in human beings worldwide [1].
After entering the stomach, H. pylori colonizes the mucus gastric layer [2] but does not traverse
the epithelial barrier [3], and therefore it is considered a non-invasive bacterium. Most of H. pylori
organisms are free living in the mucus layer, but some organisms attach to gastric epithelial cells [3]
and small numbers have been shown to invade those cells [4].
To survive into the stomach, H. pylori uses urease and α-carbonic anhydrase to generate ammonia
and HCO32´ enabling it to colonize and function at low pH conditions [5,6]. Furthermore, thanks to its
flagella and shape, H. pylori penetrates the mucus layer [7]. Once established in the inner mucus layer,
several outer membrane proteins such as BabA, SabA, AlpA, AlpB and HopZ mediate its adherence to
gastric epithelial cells. After attachment to epithelial cells, bacterial effector molecules, both secreted
(vacuolating cytotoxin (VacA) and cytotoxin-associated gene A (CagA)) or attached (components of
the type IV secretion system (CagL)), modulate gastric epithelial cell behavior leading to loss of cell
polarity, release of nutrients and chemokines (e.g., IL-8), and regulation of acid secretion via control of
gastrin and H+/K+ ATPase [8,9].
Depending on H. pylori virulence factors, environmental factors and the host immunological
status to bacterial infection, H. pylori infection can lead to several clinical complications such as gastritis,
peptic ulcer disease, gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma [10–12].
Hence, gastroenterologists use a combination of anti-secretory and antimicrobial agents to eradicate
H. pylori [13,14]. However, like other antimicrobial treatments, the therapy may select resistant H. pylori
strains [13,14]. Therefore, alternative therapies such as vaccine development against H. pylori, have
been evaluated [15].
2. Source of H. pylori-Derived Antigens
The first murine vaccine studies utilized H. felis bacterial lysates or chemically inactivated
whole-cell bacteria delivered to mice orogastrically along with cholera toxin (CT) or E. coli heat-labile
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enterotoxin (LT) as mucosal adjuvants [16]. However, the development of such vaccines would
encounter quality control and regulatory issues related to the quality and reproducibility of vaccine
preparations: therefore, defined antigens-based vaccines need to be developed.
Immunity to bacterial virulence factors is known to protect humans against bacterial infections.
A well-known example is the use of detoxified pertussis toxin, filamentus hemagglutin and pertactin
in the acellular pertussis vaccine to protect against Bordetella pertussis infections [16]. A similar strategy
has been used to develop the H. pylori vaccine [17]. Indeed, as described above, H. pylori has a large
arsenal of virulence factors that help the bacteria to colonize and persist within the stomach mucosa
of its host. One of these virulence factors, Urease is essential for colonization and pathogenic events
and due to its abundance has made it an ideal vaccine candidate [18]. In addition, proteomic analysis
identified Urease as a dominant immunogenic protein [19]. Different routes of immunization (oral,
intranasal, intrarectal, intramuscular) with urease (ureB subunit or inactive form of holoenzyme)
associated with different adjuvants (CT, LT, alum, QS21) have been shown to protect or cure H. felis or
H. pylori infections in mice and ferrets [17]. Although the first clinical trials evaluating Urease-based
vaccines have been disappointing [18], Zeng and colleagues recently provided evidence that oral
administration of H. pylori Urease B subunit fused to LT B subunit significantly reduced the acquisition
of natural H. pylori infection in children [20]. While this study demonstrated the proof of concept
for mucosal vaccine-induced protection against H. pylori infection, more work needs to be done in
order to enhance its protective capacity. Indeed, whereas the vaccine protected more than 70% of
recipients 1-year post vaccination, only 56% were protected 2–3 post vaccination [20,21]. Therefore, the
formulation of an H. pylori vaccine containing other virulence factors may be considered to enhance
vaccine efficacy. VacA is one of the virulence factors that have been evaluated as vaccine antigen.
3. Biological Activity of VacA
VacA is a secreted protein that has been reported to induce vacuolization, membrane
anion-selective channel and pore formation, disruption of endosomal and lysosomal activity, and
apoptosis in target cells. Furthermore, it has also been shown to induce IL-8 production in monocytes
derived cell line [22]. Finally, VacA has been reported to have immunomodulatory properties through
its reduction of T and B cells activation and induction of regulatory T cells differentiation, which allows
H. pylori to establish a chronic infection [23,24]. VacA and many other H. pylori derived virulence
factors, including NAP (Neutrophil-activating protein), and CagA constitute a complex network to
regulate chronic gastric injury and inflammation that lead to gastric carcinogenesis [25].
Nearly all strains of H. pylori express a form of VacA. However, polymorphism may affect VacA
toxigenic and pathogenic activity [25–27]. It is known that several regions of vacA are important
for VacA toxicity. The vacA signal region encodes the N terminus of the toxin and may be active
(type s1) or encodes an N-terminal extension, which blocks activity (s2) [26]. The vacA mid region
may bind to a wide range of cells, causing toxicity (type m1), or to a smaller range (type m2) of
cells [28]. Importantly for the development of VacA-based vaccine, mature type s1-m1 and type s2-m2
VacA toxins are about 75% identical in amino acid sequences overall [26]. Rhead and colleagues
described a third determinant of VacA toxicity, called the intermediate (i) region [29]. They showed
that two allelic variants of this region (i1 and i2) exist. This region determines toxic activity, and most
importantly, they showed a significant correlation between the i1 region and gastric cancer (GC) [29,30].
4. Detoxified VacA as Vaccine Antigen
VacA cytotoxicity causes acute gastric epithelial erosion and ulceration, which excludes the use of
the active toxin in humans [31]. VacA toxicity was found to be extremely sensitive to formaldehyde
treatment, so complete inactivation of the toxin was achievable without compromising antigenicity [32].
After the formaldehyde treatment, the toxin is still capable to bind HeLa cells but does not induce
vacuolization nor cause any epithelial damage when administered into the stomach of mice [32].
Moreover, the formaldehyde treated toxin retained some degree of its immunogenicity and was
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capable of inducing the production of neutralizing antibodies, although the neutralizing titers were
3.5 fold lower than those induced by untreated toxin [32]. Additionally, whole recombinant VacA
molecule expressed in Escherichia coli and purified by affinity chromatography is nontoxic [33] and is
a very convenient source of vaccine antigen. Indeed, when comparing to the native oligomeric toxin
purified from cultures of H. pylori, the E. coli-expressed recombinant VacA was inactive in a HeLa
cell assay of vacuolization and failed at inducing high titers of neutralizing antibodies in rabbits.
Hence, the neutralizing epitopes in the native toxin protein are likely to be conformational and may
exist only when the protein folds correctly into its native structure [33].
5. Preclinical Studies of the VacA-Based Vaccine
Significant levels of protection were achieved when infected mice were therapeutically vaccinated
intragastrically with the non-toxic recombinant VacA combined with the non-toxic mutant of LT,
LTK63. Importantly, therapeutic vaccination not only successfully eradicates H. pylori infection but
also prevents a subsequent reinfection in the majority of vaccinated animals [34]. The results of
prophylactic vaccination in animal models were also encouraging. Immunization with recombinant
VacA, together with mucosal adjuvants, confers protection in mice [35]. Although vaccine-induced
protection is not dependent on neutralizing antibodies [33], the whole VacA molecule was required
to achieve protection. Indeed, the two VacA fragments TOX58 or TOX37 individually expressed,
purified and used as antigen were unable to elicit significant protection against experimental H. pylori
challenge [35]. An interesting alternative approach to the use of the whole VacA molecule has been
published by Liu, K.Y. et al. The authors fused a fragment of VacA (aa 744–805) that contains CD4+
T cell epitopes to CagA and urease B fragments and expressed the fusion protein into an attenuated
Salmonella vector [36]. Oral therapeutic immunization with this attenuated Salmonella expressing the
CagA-VacA-UreB fusion protein, significantly decreased H. pylori colonization [36].
6. Anti-VacA Immune Response in Infected Individuals
Anti-VacA antibodies are present in serum and gastric juice from the majority of H. pylori-infected
individuals [37] and neutralizing IgG anti-VacA antibodies are sometimes detectable in humans [38].
In addition, it has been shown that CD4+ lymphocytes isolated from the gastric epithelium
of H. pylori-infected individuals proliferate in an antigen-dependent manner in the presence of
VacA [39,40]. Although T and B cell responses directed toward VacA are present in infected hosts,
the immune response is not sufficient to eradicate the established H. pylori infection. However, the
detected immune responses directed toward VacA in chronically infected people demonstrate that
VacA is immunogenic in the human population and might be a good candidate as vaccine antigen.
7. Impact of VacA Diversity on Vaccine-Induced Protection
Immunization with purified type s1-m1 VacA conferred protection against subsequent challenge
with two H. pylori strains that produced vacuolating toxin activity in vitro. However, it failed to
protect against challenge with a wild-type Tox´ strain that lacked detectable toxic activity for HeLa
cells [35,41]. It is now known that many H. pylori strains that lack toxic activity (Tox´) for HeLa cells
contain type s1-m2 or s2-m2 vacA alleles [26,35,41]. Based on these results, it can be speculated that the
failure of an s1-m1 VacA antigen to induce protective immunity against a Tox´ strain may be due to
antigenic diversity among different VacA proteins. In particular, it is possible that T epitopes present
in the type s1-m1 VacA fail to cross-react with those present in the type s2-m2 VacA. Therefore, if
VacA is to be used as a vaccine antigen, it might be appropriate to immunize with pooled VacA
antigens derived from several different VacA families and/or include additional virulence factors of
H. pylori [17].
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8. VacA-Based Vaccine in Human Trials
Malfertheiner P et al. evaluated a multicomponent vaccine composed of purified recombinant
VacA, CagA and NAP in a human phase I clinical trial [42]. Previous preclinical data clearly showed
that VacA, CagA, and NAP cocktail given intramuscularly with aluminum hydroxide as adjuvant
protected dogs against a challenge with H. pylori [42] and eradicated experimental infection [43].
The vaccine was next injected intra-muscularly to healthy, H. pylori-negative human volunteers [42].
The vaccine was well tolerated and elicited a long lasting serum antibody response in many subjects
against VacA. In vitro, VacA restimulation of peripheral blood mononuclear cells induced cellular
proliferation, which was paralleled by production of IFN-γ, suggesting that the vaccine had induced
antigen-specific T-cell responses. Remarkably, a booster immunization 18–24 months after primary
immunization elicited a strong anamnestic antibody response to VacA in all subjects, and VacA specific
production of IFN-γ can be detected after in vitro VacA stimulation of peripheral blood mononuclear
cells. These results suggested that the vaccine induced long-lasting immunity and immunologic
memory in the B and T cell populations [42]. Although the results of this clinical trial were clearly
positive and established that VacA is immunogenic and safe, to our knowledge this vaccine candidate
did not progress to phase II study.
9. The Vaccine-Induced Protective Immune Responses
The demonstration that VacA injected to healthy individuals induces an anamnestic T cells
response is of particular interest [42]. Indeed, preclinical studies clearly established the necessity
to induce a Helicobacter specific CD4+ T cell response associated with an inflammatory reaction to
reduce Helicobacter infection [44]. Since, T-cell responses directed against VacA have been detected in
individuals chronically infected with H. pylori [39,40] or in heathly individuals injected intramuscularly
with VacA [42], it can be speculated that VacA specific Th1, Th2 and/or Th17 cells may play critical
roles in the vaccine-induced protection. These activated VacA specific CD4+ T cells will secrete a large
set of cytokines such as IFN-γ, IL-17 and TNFα that promote the recruitment and the activation of
inflammatory cells such as neutrophils [45], inflammatory monocytes [46] or mast cells [47] which
participate to the reduction of bacterial load. In addition, our group recently provided evidence that
Th17 cells infiltrating the gastric mucosa of vaccinated mice produce IL-22 and that IL-22-induced
antimicrobial peptides are key determinants of vaccine-induced protection against H. pylori in mice [48].
In respect with the clinical development of future H. pylori vaccine, these pre-clinical data suggest that it
might be of high interest to correlate the presence of circulating and/or stomach VacA-specific memory
CD4+ T cells with the vaccine efficacy: hence, providing an immune correlate of vaccine protection.
10. Conclusions
Although heterogeneity exists in the expression of VacA in H. pylori isolates, limiting its potential
as vaccine candidate if used alone, pre-clinical and clinical data clearly demonstrate the good potential
of the molecule as vaccine antigen. However, since VacA is a protein that modulates many biological
processes of gastric epithelial cells and immune cells [23–25], a complete evaluation of safety profile of
VacA has to be performed before including recombinant VacA in a vaccine preparation.
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